Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research / 부인종양
Journal of Gynecologic Oncology
; : e51-2016.
Article
em En
| WPRIM
| ID: wpr-216444
Biblioteca responsável:
WPRO
ABSTRACT
Cervical cancer is the fourth most lethal women's cancer worldwide. Current treatments against cervical cancer include surgery, radiotherapy, chemotherapy, and anti-angiogenic agents. However, despite the various treatments utilized for the treatment of cervical cancer, its disease burden remains a global issue. Persistent infection of human papillomavirus (HPV) has been identified as an essential step of pathogenesis of cervical cancer and many other cancers, and nation-wide HPV screening as well as preventative HPV vaccination program have been introduced globally. However, even though the commercially available prophylactic HPV vaccines, Gardasil (Merck) and Cervarix (GlaxoSmithKline), are effective in blocking the entry of HPV into the epithelium of cervix through generation of HPV-specific neutralizing antibodies, they cannot eliminate the pre-existing HPV infection. For these reason, other immunotherapeutic options against HPV-associated diseases, including therapeutic vaccines, have been continuously explored. Therapeutic HPV vaccines enhance cell-mediated immunity targeting HPV E6 and E7 antigens by modulating primarily dendritic cells and cytotoxic T lymphocyte. Our review will cover various therapeutic vaccines in development for the treatment of HPV-associated lesions and cancers. Furthermore, we will discuss the potential of immune checkpoint inhibitors that have recently been adopted and tested for their treatment efficacy against HPV-induced cervical cancer.
Palavras-chave
Texto completo:
1
Base de dados:
WPRIM
Assunto principal:
Células Dendríticas
/
Neoplasias do Colo do Útero
/
Vacinas de DNA
/
Vacinas de Subunidades Antigênicas
/
Infecções por Papillomavirus
/
Vacinas contra Papillomavirus
/
Pesquisa Translacional Biomédica
/
Vetores Genéticos
/
Imunoterapia
Limite:
Female
/
Humans
Idioma:
En
Revista:
Journal of Gynecologic Oncology
Ano de publicação:
2016
Tipo de documento:
Article